South Korea Diabetes Devices and Therapeutics Market Investment Opportunities – Analysis & Market Size by Diagnosis and Monitoring Devices, Therapeutics, Combination Drugs, Route of Administration, Type of Diabetes, Distribution Channels, End User, Compe

According to BioIntel360, diabetes market in South Korea is expected to grow by 9.5% on annual basis to reach US$3,441.4 million in 2025.

The diabetes market in the country has experienced robust growth during 2020-2024, achieving a CAGR of 10.2%. This upward trajectory is expected to continue, with the market forecast to grow at a CAGR of 7.8% during 2025-2029. By the end of 2029, the diabetes market is projected to expand from its 2024 value of USD 3,143.8 million to approximately USD 5,064.9 million.

Key Trends and Drivers in South Korea
The South Korean diabetes devices and therapeutics market is evolving through increased CGM adoption, expanded use of digital health solutions, advancements in therapeutic delivery systems, and updated regulatory frameworks. These trends are expected to intensify over the next 2–4 years, leading to enhanced patient monitoring, refined treatment adjustments, and overall market expansion.

Increase Adoption of Continuous Glucose Monitoring (CGM)
• South Korean healthcare providers are incorporating CGM systems into diabetes management in public hospitals and specialized clinics. Pilot projects in major cities such as Seoul and Busan use CGM data to support patient treatment decisions.
• Revised reimbursement policies and updated clinical guidelines from health authorities have encouraged broader CGM use. Local clinical research emphasizes the benefits of real-time glucose data in managing glycemic control.
• CGM adoption is expected to intensify as reimbursement models and clinical evidence evolve. Improved real-time monitoring will likely lead to more timely treatment adjustments and better patient outcomes.

Integrate Digital Health Solutions for Remote Monitoring
• Digital platforms that support remote monitoring and telemedicine are being implemented in diabetes care settings. Regional initiatives have introduced digital dashboards in leading hospitals to consolidate patient data for remote consultations.
• Government-led digital health strategies and investments in healthcare IT are driving the integration of remote monitoring tools. Shifts in healthcare delivery models and evolving insurance support further promote digital solutions.
• Digital health solutions are projected to grow, enhancing connectivity between patients and providers. This trend is expected to intensify, supporting more efficient clinical decision-making and patient management.

Advanced Therapeutic Delivery Systems
• Connected therapeutic devices, including smart insulin pens and automated insulin pumps, are entering the market. Clinical trials in select South Korean hospitals evaluate these devices for dosing accuracy and adherence to treatment protocols.
• Technological innovations and findings from local clinical studies support the development of these devices. Increased research and development investments and gradual adjustments in reimbursement practices drive market entry.
• The adoption of connected therapeutic devices is expected to grow steadily as clinical protocols and reimbursement models evolve. This trend may result in more precise treatment regimens and improved diabetes management.

Regulatory and Reimbursement Frameworks
• Regulatory authorities in South Korea are updating approval processes and reimbursement models to better accommodate new diabetes devices and therapies. Recent policy updates from agencies like the Ministry of Food and Drug Safety reflect efforts to streamline market access.
• National healthcare reform initiatives and cost-containment measures are prompting these regulatory adjustments. Publications highlight the need for clear reimbursement pathways to support digital and conventional diabetes care solutions.
• A more defined regulatory framework is anticipated to boost market confidence and stimulate further investments. These changes will likely intensify, paving the way for broader market growth and improved patient access to new technologies.

Competitive Landscape in South Korea
The South Korean diabetes devices and therapeutics market features a dynamic mix of multinational leaders and emerging domestic players. Recent strategic partnerships, mergers, and acquisitions are reshaping the competitive landscape, with a growing emphasis on digital integration and regulatory alignment. In the coming years, intensified competition and consolidation will drive innovation and enhance patient management across South Korea.

Analyze Current Market Conditions
• The South Korean market for diabetes care includes multinational corporations and domestic innovators. A structured reimbursement system and clear regulatory pathways support market entry and product adoption.

Key Players and New Entrants
• Multinational manufacturers maintain a strong presence through longstanding collaborations with major healthcare institutions. These companies offer comprehensive portfolios that include both monitoring devices and therapeutic systems.
• Domestic startups and technology firms are entering the market with digital health solutions and connected therapeutic devices tailored to local needs. Recent analyses show these entrants leverage pilot projects and strategic partnerships with regional hospitals.

Review Recent Partnerships, Mergers, and Acquisitions
• Recent publications detail partnerships between established firms and local innovators to enhance device connectivity and data integration. Mergers and acquisitions in the past 12 months indicate efforts to consolidate expertise and expand product offerings in the market.
• These strategic activities contribute to a more interconnected market, fostering shared innovation and regulatory compliance. Consolidation trends align product development with the evolving needs of South Korea’s healthcare system.

Future Competitive Dynamics (Next 2–4 Years)
• The competitive landscape is expected to evolve with further consolidation as multinational firms expand digital health capabilities and local entrants secure strategic partnerships. Industry reports suggest a segmentation between providers of traditional devices and those focusing on digital innovations.
• Intensified competition is likely to drive product innovation and refine patient management strategies. Over the next 2–4 years, strategic collaborations and market consolidation are expected to reinforce South Korea's competitive positioning.

This report provides a detailed data-centric analysis of the diabetes industry in South Korea, covering market opportunities and analysis across a range of diagnosis and monitoring devices, therapeutics, domains. With over 50+ KPIs at the country level, this report provides a comprehensive understanding of diabetes market dynamics, market size and forecast, and market share statistics.

BioIntel360’s research methodology is based on industry best practices. Its unbiased analysis leverages a proprietary analytics platform to offer a detailed view of emerging business and investment market opportunities.

Scope

This report provides an in-depth, data-centric analysis of the South Korea diabetes devices and therapeutics market 2020-2029. Below is a summary of key market segments:

Diabetes Devices and Therapeutics Market Share by Category
• Diagnosis and Monitoring Devices
• Therapeutics

Diabetes Devices and Therapeutics Market Share by Diagnosis and Monitoring Devices
• Blood Glucose Monitoring Devices
• Insulin Delivery Devices
• Diabetes Management and Mobile Applications
• Artificial Pancreas Devices

Diabetes Devices and Therapeutics Market Share by Blood Glucose Monitoring Devices
• Self-Monitoring Blood Glucose Devices
• Continuous Blood Glucose Monitoring Devices
• Test Strips
• Lancets

Diabetes Devices and Therapeutics Market Share by Insulin Delivery Devices
• Insulin Pumps
• Insulin Pens
• Insulin Syringes

Diabetes Devices and Therapeutics Market Share by Therapeutics
• Oral Anti-Diabetic Drugs
• Insulin
• Non-Insulin Injectable Drugs
• Combination Drugs

Diabetes Devices and Therapeutics Market Share by Oral Anti-Diabetic Drugs
• Alpha-Glucosidase Inhibitors
• DPP-4 Inhibitors
• SGLT-2 Inhibitors

Diabetes Devices and Therapeutics Market Share by Insulin
• Basal or Long-Acting
• Bolus or Fast-Acting
• Traditional Human Insulin Drugs
• Insulin Biosimilars

Diabetes Devices and Therapeutics Market Share by Non-Insulin Injectable Drugs
• GLP-1 Receptor Agonists
• Amylin Analogue

Diabetes Devices and Therapeutics Market Share by Combination Drugs
• Combination Insulin
• Oral Combination

Diabetes Devices and Therapeutics Market Share by Route of Administration
• Subcutaneous
• Intravenous
• Others

Diabetes Devices and Therapeutics Market Share by Type of Diabetes
• Type 1 Diabetes
• Type 2 Diabetes

Diabetes Devices and Therapeutics Market Share by Distribution Channels
• Online Pharmacies
• Hospital Pharmacies
• Retail Pharmacies

Diabetes Devices and Therapeutics Market Share by End User
• Hospitals
• Diabetes Clinics
• Homecare

Reasons to Buy

• Comprehensive understanding of market structure and dynamics: Gain a detailed view of the diabetes devices and therapeutics market, including category-level segmentation (Diagnosis & Monitoring Devices and Therapeutics) and sub-segmentation by product type, route of administration, type of diabetes, distribution channel, and end user.

• Identify high-growth segments and strategic investment areas: Use segment-wise market sizing and forecasting to identify opportunities in areas such as continuous glucose monitoring, insulin delivery technologies, oral anti-diabetic drugs, and biosimilars. Tailor your market entry or expansion strategies accordingly.

• Benchmark performance across distribution and care settings: Access share analysis across online, hospital, and retail pharmacies, and evaluate usage patterns across hospitals, diabetes clinics, and homecare to support channel-specific planning and resource allocation.